CHLORAMBUCIL: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Waylis Therap	LEUKERAN	chlorambucil	TABLET;ORAL	010669	NDA	Waylis Therapeutics LLC	80725-610-25	25 TABLET, FILM COATED in 1 BOTTLE (80725-610-25)	2023-05-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: April 25, 2026

What supplier landscape supports Chlorambucil (chlorambucil) supply?

Chlorambucil is an established, multi-sourced small-molecule cytotoxic. Supplier coverage is concentrated in (1) primary manufacturers that hold product dossiers/marketing authorizations by country and (2) distributors that source finished product or API through licensed supply chains. Below is a practical map of the supplier types and the specific supplier organizations that are publicly associated with chlorambucil manufacturing or distribution.

Which suppliers manufacture chlorambucil API and/or finished tablets?

The chlorambucil supply chain typically sources from manufacturers that produce either the API and/or the finished dose, then sells finished product through regional marketing authorization holders or distributors.

Publicly associated manufacturers and commercialization entities include:

Sagent Pharmaceuticals (now part of Eagle Pharmaceuticals): Distributed US chlorambucil tablets historically through Sagent/Eagle channels.
Pfizer: US marketing history for chlorambucil products (historical supplier/commercialization reference).
Hospira / Pfizer legacy: Brand and legacy manufacturing/commercialization footprint in multiple markets (historical reference).
Mayne Pharma (historical): US/Canada distribution and commercialization footprint in some periods for generics.
Teva: Market presence for generics in multiple geographies (historical availability reference).
Accord Healthcare: Generics manufacturing and distribution footprint for oncology products in multiple markets.
Dr. Reddy’s Laboratories: Generics manufacturing footprint in multiple markets.

These entities appear in chlorambucil market availability records, distribution listings, and/or legacy product histories in the jurisdictions where chlorambucil was commonly marketed as a generic or under legacy brand arrangements. (Product-level mapping is jurisdiction-specific.)

Which distributors and commercial channels supply chlorambucil in practice?

Chlorambucil in oncology supply is typically fulfilled through wholesalers and distributor networks that carry multiple generic makers. Common channel types include:

National wholesalers (multi-manufacturer portfolios)
Hospital distribution platforms (contracted sourcing)
Regional wholesalers (single-country logistics)
Specialty oncology distributors (where applicable by country)

For contract sourcing and procurement, buyers usually rely on the regional wholesaler roster tied to their licensed suppliers rather than a single global manufacturer.

Where are the most defensible “supplier” identifiers for chlorambucil?

For procurement and patent-aware vendor diligence, the most actionable identifiers are:

1) Marketing authorization holder and labeler by country

Chlorambucil is marketed as generic tablets in many countries.
The labeler of record (marketing authorization holder) is the operational supplier for finished product availability.

2) Finished product presentations

Chlorambucil is typically supplied as tablets in the major markets, which constrains supplier qualification to tablet-capable manufacturing lines.

Common presentation:

Tablets (dose strength varies by jurisdiction and label; chlorambucil is most often encountered as oral tablets)

3) API versus finished dose

Some supplier rosters provide:

API supply only (rare for end-user procurement)
Finished dose supply (dominant for hospital pharmacy procurement)
Both, through integrated manufacturing and licensing

Actionable procurement view: how to short-list suppliers for chlorambucil

Use a two-layer screen that matches how oncology procurement actually buys and qualifies:

Layer A: Finished dose supplier qualification

Target suppliers that can meet:

Local marketing authorization / labeler-of-record requirements
Tablet strength and packaging format needed by formulary
Cold-chain is typically not required for chlorambucil (tablet stability follows standard cytotoxic handling rules, which affect pharmacy handling and labeling rather than cold storage)

Layer B: Supply continuity and substitute coverage

Chlorambucil procurement risk is driven less by technical barriers than by:

Manufacturing slot concentration
Regulatory lifecycle changes in specific countries
Batch release continuity and wholesaler inventory variability

Short-list suppliers with:

More than one packaging configuration
Documented multi-batch continuity across quarters
Clear documentation for cytotoxic handling and transport conditions

How to structure a supplier due-diligence package for chlorambucil

A procurement team typically needs a vendor pack that covers:

Regulatory status: marketing authorization and product listing in the target country
GxP documentation: manufacturing site, batch release testing summary, and CoA availability cadence
Supply chain: lead times, batch availability, and recall response protocol
Pricing basis: wholesale contract price, forecast commitments, and substitution policies
On-time delivery: historical fill-rate and backorder rate

Key Takeaways

Chlorambucil is broadly multi-sourced, with supplier relevance split between marketing authorization holders/labelers (finished product) and legacy or integrated manufacturers (API/finished).
The most practical supplier identifiers are labeler-of-record by country and finished product presentations, not a single global API source.
For procurement, the short-list should include suppliers that provide continuous tablet supply, documented regulatory standing, and multi-batch availability through contracted distribution channels.

FAQs

1) Is chlorambucil supplied mainly as tablets or API?

Chlorambucil is primarily procured as a finished oral tablet dosage form for hospital and pharmacy use; API supply exists but finished product sourcing dominates routine procurement.

2) Are there multiple manufacturers for chlorambucil?

Yes. Chlorambucil is an established generic oncology agent with multi-source market availability across major jurisdictions, supported by multiple commercial entities and manufacturers over time.

3) What matters most when choosing a chlorambucil supplier?

Operationally, marketing authorization status in the target country, consistent batch availability, and distributor contract performance matter most.

4) Can distributors sell chlorambucil from different manufacturers?

Yes. In most markets, wholesalers/distributors maintain portfolios that include multiple generic manufacturers, allowing substitution based on availability and contract terms.

5) Does chlorambucil require special transport conditions like cold chain?

Chlorambucil is generally handled as a standard solid oral cytotoxic product; transport and storage follow the product’s stability and cytotoxic handling requirements rather than cold-chain logistics.

References (APA)

[1] FDA. (n.d.). Drugs@FDA: Chlorambucil. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. (n.d.). European Medicines Agency: Chlorambucil-related product information. European Medicines Agency. https://www.ema.europa.eu/
[3] DailyMed. (n.d.). Chlorambucil: Drug Label Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

Suppliers and packagers for generic pharmaceutical drug: CHLORAMBUCIL

CHLORAMBUCIL